Unaudited financial result for Quarter ended 30.06.2025
Awaiting price reaction for this filing.
Citurgia Biochemicals reported zero revenue from operations and no other income for Q1 FY26 (ended June 30, 2025), making it the fourth consecutive period of nil revenue. Total expenses for the quarter stood at ₹8.39 lakhs, comprising ₹3.00 lakhs in employee costs, ₹5.15 lakhs in depreciation, and ₹0.24 lakhs in other expenses. This resulted in a net loss of ₹8.39 lakhs for the quarter, compared to a loss of ₹9.00 lakhs in Q1 FY25 and ₹11.93 lakhs in Q4 FY25. For the full year FY25, the company posted a loss of ₹42.31 lakhs. Basic and diluted EPS were effectively at zero (negative). The statutory auditor G.P. Keshri & Associates issued an unmodified limited review report with no qualifications.
The company appears to be completely non-operational with no business activity generating revenue, while still incurring fixed costs like depreciation and salaries. Shareholders should be concerned about the company's viability and business continuity, as no operational revival is visible from these numbers.